10-Q: Acurx Pharmaceuticals Reports Q1 2025 Financial Results, Secures $12 Million Purchase Agreement with Lincoln Park Capital

Sentiment:

Quarterly Report 12 May 2025 8:05 PM

📋All filings for Acurx Pharmaceuticals, INC

Acurx Pharmaceuticals announces its Q1 2025 financial results, highlighting a net loss of $2.1 million and a new $12 million purchase agreement with Lincoln Park Capital.

Capital raiseThe company completed registered direct offerings in January and March 2025, generating net proceeds of $2.1 million and $0.9 million, respectively.On May 8, 2025, Acurx entered into a purchase agreement with Lincoln Park Capital for up to $12.0 million in shares of common stock.The company plans to seek additional equity financing and grant funding to sustain its operations.

Worse than expectedThe company's cash balance is projected to be insufficient to meet its anticipated cash requirements for the next 12 months.The company received a Nasdaq notification regarding non-compliance with the minimum stockholders' equity and bid price requirements.

Summary

Acurx Pharmaceuticals, a clinical-stage biopharmaceutical company, reported a net loss of $2.1 million for the three months ended March 31, 2025, compared to a net loss of $4.4 million for the same period in 2024.
Research and development expenses decreased to $0.6 million from $1.6 million year-over-year, primarily due to lower manufacturing-related costs and consulting fees.
General and administrative expenses also decreased to $1.6 million from $2.8 million, mainly due to lower professional fees and share-based compensation costs.
The company completed registered direct offerings in January and March 2025, generating net proceeds of $2.1 million and $0.9 million, respectively.
As of March 31, 2025, Acurx had a cash balance of $4.6 million, which is projected to be insufficient to meet its anticipated cash requirements for the next 12 months.
On May 8, 2025, Acurx entered into a purchase agreement with Lincoln Park Capital for up to $12.0 million in shares of common stock.
The company received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement and the minimum bid price requirement.
Acurx submitted a compliance plan to Nasdaq on May 9, 2025, to address the stockholders' equity deficiency.
The company is developing ibezapolstat for the treatment of C. difficile infections (CDI) and has an early-stage pipeline of antibiotic product candidates.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company has reduced its net loss and secured a purchase agreement with Lincoln Park Capital, it faces significant financial challenges, including a limited cash balance and non-compliance with Nasdaq listing requirements. The going concern warning from the auditors further contributes to the negative sentiment.

Positives

The net loss decreased from $4.4 million in Q1 2024 to $2.1 million in Q1 2025.
Research and development expenses decreased by $1.0 million year-over-year.
General and administrative expenses decreased by $1.2 million year-over-year.
The company secured a purchase agreement with Lincoln Park Capital for up to $12.0 million.

Negatives

The company experienced a net loss of $2.1 million for Q1 2025.
The company's cash balance of $4.6 million is projected to be insufficient to meet its anticipated cash requirements for the next 12 months.
Acurx received a Nasdaq notification regarding non-compliance with the minimum stockholders' equity and bid price requirements.
The independent registered public accounting firm has expressed substantial doubt about the company’s ability to continue as a going concern.

Risks

The company's cash balance may not be sufficient to fund operations for the next 12 months.
The company is reliant on the success of its lead product candidate, ibezapolstat.
The company faces competition from larger and better capitalized companies.
The company is subject to the risks associated with clinical trials and regulatory approvals.
The company is subject to the risks associated with operating in foreign countries.
The company is subject to the risks associated with intellectual property litigation.
The company is subject to the risks associated with cyber incidents or attacks.
The company is subject to the risks associated with evolving privacy and data protection laws.
The company is subject to the risks associated with artificial intelligence.
The company is subject to the risks associated with the estimates and judgments made in preparing the financial statements.
The company is subject to the risks associated with the Foreign Corrupt Practices Act.
The company is subject to the risks associated with litigation.
The company is subject to the risks associated with environmental, health and safety laws and regulations.
The company is subject to the risks associated with the lack of research or reports about the business.
The company is subject to the risks associated with Delaware law containing anti-takeover provisions.
The company is subject to the risks associated with the exclusive forum for substantially all disputes between the company and its stockholders.

Future Outlook

The company plans to seek additional equity financing and grant funding to sustain its operations. Management expects to continue to incur losses for the foreseeable future.

Industry Context

The company operates in the biopharmaceutical industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The company is focused on developing a new class of antibiotics to address the growing problem of antimicrobial resistance.

Comparison to Industry Standards

It is difficult to compare Acurx's results directly to industry standards due to its clinical-stage nature and lack of product revenue.
Comparable companies in the clinical-stage biopharmaceutical industry include companies like Spero Therapeutics and Nabriva Therapeutics, which are also focused on developing novel antibiotics.
These companies often rely on equity financing and strategic partnerships to fund their operations.
Acurx's reliance on third-party manufacturers and CROs is also common in the industry.
The company's focus on addressing antimicrobial resistance aligns with global health priorities and market needs.

Stakeholder Impact

Shareholders may experience dilution due to additional equity offerings.
Employees may be affected by potential cost-cutting measures or changes in the company's strategic direction.
Customers (potential patients) may benefit from the development of new antibiotic therapies.
Suppliers and creditors may be impacted by the company's financial challenges and potential need to renegotiate terms.
The company's ability to continue as a going concern impacts all stakeholders.

Next Steps

The company intends to use the net proceeds from the offerings for working capital and other general corporate purposes.
The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement.
The company plans to continue the development of its product candidates and seek to discover and develop new product candidates.

Key Dates

Date	Description
2017-07-01	Acurx Pharmaceuticals, LLC formed in July 2017
2018-02-01	Company operations commencing in February 2018
2018-02-01	Company purchased the active pharmaceutical ingredient, the intellectual property and other rights to an antibiotic product candidate known as GLS362E (renamed ACX-362E and now approved for non-proprietary name, ibezapolstat) (the Asset) from GLSynthesis, Inc.
2021-06-23	Acurx Pharmaceuticals, LLC was converted into a corporation and renamed Acurx Pharmaceuticals, Inc.
2021-06-29	Company completed the IPO, issuing 2,875,000 shares of common stock at a price of $6.00 per share, with gross proceeds of approximately $17.3 million.
2022-07-27	Company completed a registered direct offering and a concurrent private placement, issuing 1,159,211 shares of common stock and 130,769 pre-funded warrants and Series A Warrants to purchase 1,289,980 shares of common stock and Series B Warrants to purchase 1,289,980 shares of common stock for gross proceeds of approximately $4.2 million.
2023-05-18	Company completed a registered direct offering and a concurrent private placement, issuing 601,851 shares of common stock, 731,482 pre-funded warrants, Series C Warrants to purchase 1,333,333 shares of common stock and Series D Warrants to purchase 1,333,333 shares of common stock for gross proceeds of approximately $4.0 million.
2023-11-15	Company entered into a Sales Agreement and established an At-the-Market offering (the ATM Program), pursuant to which the Company may offer and sell, from time to time through A.G.P/Alliance Global Partners, as sales agent, shares of its common stock having an aggregate offering price of up to $17.0 million.
2024-01-06	Company suspended the ATM program.
2025-01-06	Company completed a registered direct offering and concurrent private placement for net proceeds of $2.1 million after deducting placement agent fees and offering expenses.
2025-03-06	Company completed a registered direct offering and concurrent private placement for net proceeds of $0.9 million after deducting placement agent fees and offering expenses.
2025-03-25	Company received a letter from the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying us that we are not in compliance with the minimum stockholders equity requirement for continued listing on The Nasdaq Capital Market
2025-05-08	Company entered into a purchase agreement (the Purchase Agreement) with Lincoln Park Capital Fund, LLC (Lincoln Park), pursuant to which Lincoln Park committed to purchase up to $12.0 million in shares of our common stock, $0.001 par value per share.
2025-05-09	Company submitted the Compliance plan on May 9, 2025.

Keywords

ibezapolstat, Acurx Pharmaceuticals, financial results, registered direct offering, Lincoln Park Capital, Nasdaq compliance, C. difficile, antibiotics, clinical trials, net loss, research and development, share-based compensation, going concern, stockholders equity, minimum bid price

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.